natgillin/translations-raw huggingface dataset:
The cumulative incidence rate curves showed that time to first major relapse was longer in patients with rituximab starting from month 2 and was maintained up to month 28 (Figure 3). 
Krivulje kumulativnih stopenj incidence so pokazale, da je bil čas do prvega hujšega recidiva pri bolnikih, ki so prejemali zdravilo rituksimab, daljši, in sicer od 2. meseca naprej; to se je ohranilo do
Vascular disorders hypertension, orthostatic hypotension, hypotension vasculitis (predominate ly cutaneous), leukocytoclas tic vasculitis 
Žilne bolezni hipertenzija, ortostatska hipotenzija, hipotenzija vaskulitis (pretežno kožni), levkocitoklastični vaskulitis
Although rituximab is not myelosuppressive in monotherapy, caution should be exercised when considering treatment of patients with neutrophils < 1.5 x 109/L and/or platelet counts < 75 x 109/L as clinical experience in this population is limited. 
Čeprav zdravilo rituksimab pri samostojnem zdravljenju ne deluje mielosupresivno, je potrebna previdnost pri bolnikih, ki imajo število nevtrofilcev < 1,5 x 109/l in/ali trombocitov < 75 x 109/l.
Patients were excluded from the study in relapsed/refractory CLL if they had previously been treated with monoclonal antibodies or if they were refractory (defined as failure to achieve a partial remission for at least 6 months) to fludarabine or any nucleoside analogue. 
Iz študije pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, so bili izključeni tisti, ki so bili predhodno zdravljeni z monoklonskimi protitelesi ali ki se niso odzvali na zdravljenje (ki niso dosegli delne remisije za vsaj 6 mesecev) s fludarabinom ali katerim drugim nukleozidnim analogom.
Excipients: This medicinal product contains 11.5 mmol (or 263.2 mg) sodium per 50 mL vial. 
Pomožne snovi: To zdravilo vsebuje 11,5 mmol (ali 263,2 mg) natrija na 50-ml vialo.
In the majority of these cases, rituximab was administered with chemotherapy. 
V večini teh primerov so rituksimab uporabili skupaj s kemoterapijo.
Late neutropenia 
Pozna nevtropenija
The prepared Ritemvia solution should be administered as an intravenous infusion through a dedicated line. 
Pripravljeno raztopino zdravila Ritemvia dajemo kot intravensko infuzijo skozi poseben kanal.
3 see also section haematologic adverse reactions below 
3 Glejte tudi poglavje hematološki neželeni učinki spodaj.
The incidence of grade 3/4 blood and lymphatic adverse events was higher in elderly patients compared to younger patients (< 65 years), with previously untreated or relapsed/refractory CLL. 
Incidenca neželenih dogodkov krvi in limfatičnega sistema 3. ali 4. stopnje je bila pri bolnikih s KLL, ki predhodno še niso bili zdravljeni ali pri katerih se je bolezen ponovila oziroma se na predhodno zdravljenje niso odzvali, višja pri starejših bolnikih v primerjavi z mlajšimi bolniki (< 65 let).
Maintenance infusions of rituximab 500 mg were administered at months 12 and 18. 
Vzdrževalni infuziji 500 mg zdravila rituksimab sta bili uporabljeni 12. in 18. mesec.
The incidence of infusion-related symptoms decreased substantially with subsequent infusions and is < 1% of patients by the eighth cycle of rituximab-containing treatment. 
Incidenca simptomov in znakov, povezanih z infuzijo, se je z nadaljnjimi infuzijami precej zmanjšala in je bila do osmega cikla zdravljenja z rituksimabom < 1%.
Following two intravenous infusions of rituximab at a dose of 1000 mg, two weeks apart, the mean terminal half-life was 20.8 days (range, 8.58 to 35.9 days), mean systemic clearance was 0.23 L/day (range, 0.091 to 0.67 L/day), and mean steady-state distribution volume was 4.6 L (range, 1.7 to 7.51 L). 
Po dveh intravenskih infuzijah rituksimaba v odmerku 1.000 mg v razmiku dveh tednov je bil povprečni končni razpolovni čas 20,8 dni (razpon 8,58 do 35,9 dni), povprečni sistemski očistek je bil 0,23 l/dan (razpon 0,091 do 0,67 l/dan), povprečen volumen distribucije v stanju dinamičnega ravnovesja pa 4,6 l (razpon 1,7 do 7,51 l).
The PK parameters of rituximab in these patients appear similar to what has been observed in rheumatoid arthritis patients. 
Farmakokinetični parametri rituksimaba so bili pri teh bolnikih podobni kot pri bolnikih z revmatoidnim artritisom.
In case of such an event with a suspected relationship to rituximab, treatment should be permanently discontinued. 
Če se pojavi tak neželen učinek z možno povezavo z zdravilom rituksimab, je treba zdravljenje trajno ukiniti.
In patients with relapsed/refractory CLL, the incidence of grade 3/4 hepatitis B infection (reactivation and primary infection) was 2% in R-FC vs. 0% FC. 
Pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, je bila incidenca okužbe s hepatitisom B stopnje 3 ali 4 (reaktivacija in primarna okužba) 2% pri R-FC v primerjavi z 0% pri FC (fludarabin in ciklofosfamid).
• high blood sugar level, weight loss, swelling in the face and body, high levels of the enzyme “lactate dehydrogenase (LDH)” in the blood, low calcium levels in the blood 
velika koncentracija krvnega sladkorja, hujšanje, oteklost obraza in telesa, visoka raven encima LDH v krvi, majhna koncentracija kalcija v krvi,
Patients received 2 × 1000 mg of rituximab separated by an interval of two weeks; in addition to methotrexate (10-25 mg/week). 
Bolniki so prejeli 2 x 1000 mg rituksimaba v razmiku 2 tednov in metotreksat (10 do 25 mg/teden).
The mean Cmax (N=15) was 408 µg/mL (range, 97 - 764 µg/mL) after the fifth 500 mg/ m2 infusion and the mean terminal half-life was 32 days (range, 14 - 62 days). 
Povprečna Cmax (n=15) je bila 408 µg/ml (od 97 do 764 µg/ml) po peti infuziji 500 mg/m2, povprečni končni razpolovni čas pa je bil 32 dni (od 14 do 62 dni).
Bulky disease 
Obsežna bolezen
Figure 4: Number of patients who were off or minimal corticosteroid (≤ 10mg/day) therapy over time 
Slika 4: Število bolnikov brez kortikosteroidnega zdravljenja ali z minimalnim kortikosteroidnim zdravljenjem (≤ 10mg/dan) glede na čas zdravljenja
Consideration should be given to the use of a reduced infusion rate for the first infusion in these patients or a split dosing over two days during the first cycle and any subsequent cycles if the lymphocyte count is still > 25 x 109/L. 
Že za prvo infuzijo pri teh bolnikih razmislimo o zmanjšanju pretoka ali delitvi odmerka na dva dneva v prvem ciklu in, če je število limfocitov še vedno večje od 25 x 109/l, tudi v vseh nadaljnjih ciklih.
The incidence of IRR decreased with subsequent courses (see section 4.8). 
Incidenca reakcij, povezanih z infuzijo, se je z nadaljnjimi cikli zdravljenja zmanjšala (glejte poglavje 4.8).
Severe skin reactions such as Toxic Epidermal Necrolysis (Lyell's syndrome) and Stevens-Johnson syndrome, some with fatal outcome, have been reported (see section 4.8). 
Poročali so o hudih kožnih reakcijah, kot sta toksična epidermalna nekroliza (Lyellov sindrom) in Stevens-Johnsonov sindrom; nekatere so se končale s smrtnim izidom (glejte poglavje 4.8).
Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, should be treated with extreme caution. 
Bolnike z veliko tumorsko maso ali velikim številom (≥ 25 x 109/l) krožečih malignih celic, kot so bolniki s KLL, pri katerih obstaja večje tveganje izjemno hudega sindroma sproščanja citokinov, zdravimo le izjemno pazljivo.
Patients with a high tumour burden or with a high number (≥ 25 x 109/L) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, should be treated with extreme caution. 
Bolnike z veliko tumorsko maso ali velikim številom (≥ 25 x 109/l) krožečih malignih celic, kot so bolniki s KLL, pri katerih obstaja večje tveganje izjemno hudega sindroma sproščanja citokinov, zdravimo izjemno pazljivo.
Figure 1: Change from baseline of DAS28-ESR by baseline autoantibody status 
Sprememba v DAS28-ESR od izhodišča glede na izhodiščno stanje protiteles.
Clear Type I glass vials with butyl rubber stopper containing 500 mg of rituximab in 50 mL. 
Prozorne viale iz stekla tipa I z gumijastim zamaškom, ki vsebujejo 500 mg rituksimaba v 50 ml.
Table 18 Percentage of PV patients who achieved complete remission off corticosteroid therapy for two months or more at month 24 (Intent-to-Treat Population - PV) 
Odstotek bolnikov z navadnim pemfigusom, ki so po 24 mesecih dosegli popolno remisijo brez kortikosteroidnega zdravljenja v obdobju dveh mesecev ali več (populacija z-namenom-zdravljenja - navadni pemfigus)
This is equivalent to 13.2% of the recommended maximum daily dietary intake of sodium for an adult. 
13,2% priporočenega največjega dnevnega vnosa natrija s hrano za odrasle osebe.
Figure 4: Number of patients who were off or on minimal corticosteroid (≤10 mg/day) therapy over time 
Slika 4: Število bolnikov brez kortikosteroidnega zdravljenja ali z minimalnim kortikosteroidnim zdravljenjem (≤ 10 mg/dan) glede na čas zdravljenja
Based on a population pharmacokinetic analysis in 298 NHL patients who received single or multiple infusions of rituximab as a single agent or in combination with CHOP therapy (applied rituximab doses ranged from 100 to 500 mg/m2), the typical population estimates of nonspecific clearance (CL1), specific clearance (CL2) likely contributed by B cells or tumour burden, and central compartment volume of distribution (V1) were 0.14 L/day, 0.59 L/day, and 2.7 L, respectively. 
Iz populacijske farmakokinetične analize pri 298 bolnikih z ne-Hodgkinovim limfomom, ki so prejeli enkratno ali večkratno infuzijo rituksimaba (odmerki od 100 do 500 mg/m2) samostojno ali v kombinaciji s CHOP, lahko ocenimo nespecifični očistek tipične populacije bolnikov (Cl1): 0,14 l/dan, specifični očistek (Cl2), h kateremu je verjetno pripomoglo breme celic B ali tumorsko breme:
The safety profile of rituximab in patients with moderate to severe rheumatoid arthritis (RA) is summarised in the sections below. 
Varnostni profil rituksimaba pri bolnikih z zelo aktivnim revmatoidnim artritisom je povzet v spodnjem besedilu.
Radiographic analysis at 2 years in Trial 1 demonstrated significantly reduced progression of structural joint damage in patients receiving rituximab in combination with methotrexate compared to methotrexate alone as well as a significantly higher proportion of patients with no progression of joint damage over the 2 year period. 
1 je po 2 letih pokazala značilno manjše napredovanje strukturnih okvar sklepov pri bolnikih, ki so prejemali rituksimab v kombinaciji z metotreksatom, kot pri tistih, ki so prejemali samo metotreksat; prav tako je pokazala značilno večji delež bolnikov brez napredovanja okvar sklepov v 2-letnem obdobju.
This medicinal product contains 263.2 mg sodium per 50 mL vial, equivalent to 13.2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.For the full list of excipients, see section 6.1. 
To zdravilo vsebuje 263,2 mg natrija na 50 mL viale, kar je enako 13,2% največjega dnevnega vnosa natrija za odrasle osebe, ki ga priporoča SZO in znaša 2 g.
42-months p = 0.029 
42 mesecev p = 0,029
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and very rare (< 1/10,000). 
Pogostnost je opredeljena kot zelo pogosta (≥ 1/10), pogosta (≥ 1/100 do < 1/10), občasna (> 1/1000 do ≤ 1/100) in zelo redka (≤ 1/10000).
The majority of patients had received rituximab in combination with chemotherapy or as part of a haematopoietic stem cell transplant. 
Večina bolnikov je prejemala rituksimab v kombinaciji s kemoterapijo ali v okviru presaditve krvotvornih matičnih celic.
The incidence, types and severity of IRRs were consistent with that observed historically. 
Incidenca, vrsta in resnost neželenih reakcij, povezanih z infuzijo, je bila podobna, kot opažena v preteklosti.
Cardiovascular adverse reactions 
Kardiovaskularni neželeni učinki
Clear Type I glass vials with butyl rubber stopper containing 100 mg of rituximab in 10 mL. 
Prozorne viale iz stekla tipa I z gumijastim zamaškom, ki vsebujejo 100 mg rituksimaba v 10 ml.
And 
O
You may be asked not to take these other medicines 12 hours before you are given Ritemvia. 
Morda vam bo naročil, da ne jemljite teh drugih zdravil 12
Physicians should exercise caution when considering the use of rituximab in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see section 4.8). 
Pri odločanju za uporabo zdravila rituksimab morajo biti zdravniki previdni pri bolnikih z anamnezo ponavljajočih se ali kroničnih okužb ali s sočasnimi boleznimi, zaradi katerih so lahko bolniki dodatno nagnjeni k resnim okužbam (glejte poglavje 4.8).
In a prospective, open label, international, multicentre, phase III trial, 465 patients with relapsed/refractory follicular lymphoma were randomised in a first step to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; n=231) or rituximab plus CHOP (R-CHOP, n=234). 
V prospektivnem, odprtem, mednarodnem, multicentričnem preskušanju faze III je bilo 465 bolnikov, pri katerih so se folikularni limfomi ponovili ali se niso odzvali na zdravljenje, randomiziranih v prvi del indukcijskega zdravljenja s CHOP (ciklofosfamid, doksorubicin, vinkristin, prednizolon, n=231) ali zdravljenje z rituksimabom in CHOP (R-CHOP, n=234).
Subsequent infusions may be administered no sooner than 16 weeks following the previous infusion. 
Nadaljnje infuzije se lahko dajo po preteku najmanj 16 tednov po prejšnji infuziji.
The Patient information about Ritemvia should contain the following key elements: 
Gradivo za bolnika o zdravilu Ritemvia mora vsebovati naslednje ključne vsebine:
Table 2 Summary of adverse drug reactions reported in clinical trials or during post-marketing surveillance occurring in patients with rheumatoid arthritis receiving rituximab 
Povzetek neželenih učinkov, o katerih so poročali med kliničnimi študijami ali po prihodu zdravila na trg pri bolnikih z revmatoidnim artritisom, ki so prejemali zdravilo rituksimab.
This medicinal product contains 52.6 mg sodium per 10 mL vial, equivalent to 2.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.For the full list of excipients, see section 6.1. 
To zdravilo vsebuje 52,6 mg natrija na 10 mL viale, kar je enako 2,6% največjega dnevnega vnosa natrija za odrasle osebe, ki ga priporoča SZO in znaša 2 g.
Mean change DAS28-ESR ‐1.97** Significance levels were defined as * p<0.05, **p<0.001, ***p<0.0001. 
Ravni signifikantnosti so bile opredeljene kot *p < 0,05; **p < 0,001; ***p < 0,0001.
In a prospective, open label, international, multicentre, phase III trial 1193 patients with previously untreated advanced follicular lymphoma received induction therapy with R-CHOP (n=881), R-CVP (n=268) or R-FCM (n=44), according to the investigators' choice. 
V prospektivnem, odprtem, mednarodnem, multicentričnem preskušanju III. faze je 1193 bolnikov s predhodno nezdravljenimi folikularnimi limfomi prejelo indukcijsko zdravljenje z R-CHOP (n=881), RCVP (n=268) ali R-FCM (n=44) po presoji raziskovalca.
In a non-randomised study, patients with relapsed low-grade NHL who received rituximab monotherapy when compared to healthy untreated controls had a lower rate of response to vaccination with tetanus recall antigen (16% vs. 81%) and Keyhole Limpet Haemocyanin (KLH) neoantigen (4% vs. 76% when assessed for >2-fold increase in antibody titer). 
V nerandomizirani študiji so imeli bolniki, ki so prejeli samostojno zdravljenje z rituksimabom ob ponovitvi nizkomalignega NHL, v primerjavi z zdravimi kontrolnimi osebami, ki niso prejele zdravila, v manjšem deležu dogovorili nižji delež odgovora na cepljenje s cepivom proti tetanusu (recall antigen) (16% v primerjavi z 81%) in neoantigenom KLH (Keyhole Limpet Haemocyanin) (4% v primerjavi s 76%, ko so določevali > 2-kratno povečanje v titru protiteles).
• The active ingredient in Ritemvia is called rituximab. 
• Zdravilna učinkovina zdravila Ritemvia je rituksimab.
The two treatment groups were well balanced with regards to baseline characteristics and disease status. 
Terapevtski skupini sta bili ob začetku zdravljenja dobro uravnoteženi glede na osnovne lastnosti in stanje bolezni.
Skin and subcutaneous tissue disorders alopecia toxic epidermal necrolysis (Lyell's syndrome), StevensJohnson syndrome5 
Bolezni kože in podkožja alopecija toksična epidermalna nekroliza (Lyellov sindrom), StevensJohnsonov sindrom5
Patients randomised to the standard-dose prednisone group received an initial 1 mg/kg/day oral prednisone tapered off over 12 months if they had moderate disease or 1.5 mg/kg/day oral prednisone tapered off over 18 months if they had severe disease. 
Bolniki, randomizirani v skupino s standardnim odmerkom prednizona, so uvodoma prejeli 1 mg/kg/dan peroralnega prednizona z zmanjševanjem odmerka v obdobju 12 mesecev, če so imeli zmerno bolezen, ali 1,5 mg/kg/dan peroralnega prednizona z zmanjševanjem odmerka v obdobju 18 mesecev, če so imeli hudo bolezen.
3 patients (8%) in the rituximab group experienced a total of 5 serious infections (Pneumocystis jirovecii pneumonia, infective thrombosis, intervertebral discitis, lung infection, Staphylococcal sepsis) and one patient (3%) in the standard-dose prednisone group experienced a serious infection (Pneumocystis jirovecii pneumonia). 
V skupini z zdravilom rituksimab se je pri 3 bolnikih (8%) pojavilo 5 resnih okužb (pljučnica zaradi Pneumocystis jirovecii, infekcijska tromboza, intervertebralni disciitis, okužba pljuč, stafilokokna sepsa); v skupini s standardnim odmerkom prednizona se je resna okužba (pljučnica zaradi Pneumocystis jirovecii) pojavila pri 1 bolniku (3%).
serum sickness-like reaction 
reakcija, podobna serumski bolezni
The safety profile of rituximab in combination with short-term, low-dose glucocorticoids in the treatment of patients with pemphigus vulgaris was studied in a Phase 3, randomised, controlled, multicenter, open-label study in pemphigus patients that included 38 pemphigus vulgaris (PV) patients randomised to the rituximab group. 
Varnostne značilnosti zdravila rituksimab v kombinaciji s kratkotrajno uporabo majhnih odmerkov glukokortikoida za zdravljenje bolnikov z navadnim pemfigusom so raziskali v randomizirani, kontrolirani, multicentrični odprti študiji faze III, v kateri so 38 bolnikov randomizirali v skupino, ki je prejemala rituksimab.
Excipients: This medicinal product contains 2.3 mmol (or 52.6 mg) sodium per 10 mL vial. 
Pomožnesnovi: To zdravilo vsebuje 2,3 mmol (ali 52,6 mg) natrija na 10-ml vialo.
Multiple courses of treatment are associated with a similar ADR profile to that observed following first exposure. 
Pri večkratnem zdravljenju je profil neželenih učinkov podoben tistemu, ki so ga opazili ob prvem zdravljenju.
decreased IgG 
Koncentracija IgG
In addition to adverse reactions seen in RA clinical trials for rituximab, progressive multifocal leukoencephalopathy (PML) (see section 4.4) and serum sickness-like reaction have been reported during post marketing experience. 
Poleg neželenih učinkov, o katerih so poročali v kliničnih preskušanjih uporabe rituksimaba pri revmatoidnem artritisu, so po prihodu zdravila na trg poročali tudi o progresivni multifokalni levkoencefalopatiji (PML) (glejte poglavje 4.4) ter reakciji, podobni serumski bolezni.
Therefore, in patients with a known cardiac history, and those who experienced prior cardiopulmonary adverse reactions the risk of cardiovascular complications resulting from infusion reactions should be considered before treatment with rituximab and patients closely monitored during administration. 
Pred zdravljenjem z zdravilom rituksimab moramo pri bolnikih, z znanimi boleznimi srca in tistih, pri katerih so v preteklosti opazili kardio-pulmonalne neželene učinke, razmisliti o možnih kardiovaskularnih zapletih, ki lahko nastanejo kot posledica reakcij, povezanih z infuzijo, bolnike pa med dajanjem zdravila skrbno nadzorovati.
In the relapsed/refractory CLL study grade 3/4 thrombocytopenia was reported in 11% of patients in the R-FC group compared to 9% of patients in the FC group. 
V študiji pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, so o trombocitopeniji stopnje 3 ali 4 poročali pri 11% bolnikov v skupini R-FC v primerjavi z 9% v skupini FC.
Signs and symptoms included visual disturbance, headache, seizures and altered mental status, with or without associated hypertension. 
Znaki in simptomi so vključuvali motnje vida, glavobol, konvulzije in motnje zavesti, s pridruženo hipertenzijo ali brez nje.
Alopecia Pruritus 
+alopecija urtikarija,
Patients were randomised in a 1:1 ratio to receive either oral cyclophosphamide daily (2 mg/kg/day) for 3-6 months or rituximab (375 mg/m2) once weekly for 4 weeks. 
Bolnike so v razmerju 1:1 randomizirali na zdravljenje s peroralnim ciklofosfamidom (2 mg/kg/dan) vsak dan od 3 do 6 mesecev ali z rituksimabom (375 mg/m2) enkrat na teden 4 tedne.
This medicine contains 263.2 mg sodium (main component of cooking/table salt) in each 50 mL vial. 
To zdravilo vsebuje 263,2 mg natrija (glavne sestavine kuhinjske soli) na 50 mL viale.
If you get any of these, tell a doctor or nurse straight away. 
Če se pri vas pojavi kateri koli od teh znakov ali simptomov, nemudoma obvestite zdravnika ali medicinsko sestro.
These can be complemented with other appropriate markers as per local guidelines. 
To vključuje najmanj določanje statusa HBsAg in HBcAb, ki ju lahko dopolnimo z ostalimi primernimi označevalci v skladu z lokalnimi smernicami.
In these patients the rate of clinically relevant infection while on rituximab was 6.01 per 100 patient years compared to 4.97 per 100 patient years following treatment with the biologic DMARD. 
100 bolnik-let, ko so se zdravili z rituksimabom, v primerjavi s 4,97 na 100 bolnik-let po tem, ko so prejeli nadaljnje zdravljenje z biološkim DMARD.
The most commonly reported events considered as ADRs were infusion-related reactions and infections. 
Najpogosteje zabeleženi dogodki, ocenjeni kot neželeni učinki zdravila, so bile z infundiranjem povezane reakcije in okužbe.
The pharmacokinetics of rituximab were assessed following two intravenous (IV) doses of 500 mg and 1000 mg on Days 1 and 15 in four studies. 
Farmakokinetiko rituksimaba so ocenili po dveh 500 mg in 1.000 mg intravenskih odmerkih ob dnevih 1 in 15 v štirih preskušanjih.
The frequencies of ADRs reported with rituximab alone or in combination with chemotherapy are summarised in Table 1. 
Pogostnosti neželenih učinkov, zabeleženih med samostojnim zdravljenjem z rituksimabom ali v kombinaciji s kemoterapijo, so povzete v preglednici 1.
Using a cox regression analysis, the risk of experiencing progressive disease or death was reduced by 61% with rituximab maintenance treatment when compared to observation (95% CI; 45%-72%). 
Tveganje za napredovanje bolezni ali smrt je bilo zmanjšano za 61 % z vzdrževalnim zdravljenjem z rituksimabom v primerjavi z opazovano skupino (Coxova regresijska analiza, 95-% interval zaupanja: 45-72 %).
CD20 is found on both normal and malignant B cells, but not on haematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissue. 
pro-B-celicah, normalnih plazmatkah ali drugem normalnem tkivu.
Diffuse large B cell non-Hodgkin's lymphoma 
Difuzni velikocelični B ne-Hodgkinov limfom
The reactions reported were usually reversible with a reduction in rate, or interruption, of rituximab infusion and administration of an anti-pyretic, an antihistamine, and, occasionally, oxygen, intravenous saline or bronchodilators, and glucocorticoids if required. 
Reakcije, o katerih so poročali, so bile običajno reverzibilne z zmanjšanjem hitrosti ali prekinitvijo infuzije rituksimaba in dajanjem antipiretika, antihistaminika in občasno kisika, fiziološke raztopine intravensko ali bronhodilatatorja, in glukokortikoidov, če je bilo to potrebno.